CLDF Title
Home | Contact Us | Bookmark
HEPATITIS
HBV HCV HDV
CLD HEALTH OUTCOMES
CIRRHOSIS
CIRRHOSIS HEPATIC ENCEPHALOPATHY (HE) HEPATORENAL SYNDROME (HRS)
NASH
CHOLESTATIC
PRIMARY BILIARY CHOLANGITIS (PBC)
ALCOHOL LIVER DISEASE PEDIATRIC LIVER DISEASE
About CLDF
Board of Trustees Embassy of Education CLDF Committees 2023 GI Fellow Board of Advisors
Embassy of Education
Publications Webcasts Abstract Library Committee Members
 
NASH Single Disease Content  
Publications
 
Slide Library
   Released: 2023
test
NASH PATHway to Treatment
Michael Charlton, MD
Rohit Loomba, MD
Maru E. Rinella, MD
97 slides
 
 
   Released: 2023
test
Advances in NAFLD/NASH
Kris V. Kowdley, MD
55 slides
 
 
   Released: 2022
test
 
   Released: 2022
test
 
   Released: 2022
test
Pearls and Pitfalls: Update on emerging therapies in NASH
Michael Charlton, MD & Rohit Loomba, MD
97 slides
 
 
 
 
 
Webcast Library
Liver Connect 2023   Educational Webcast
NASH Connect 2023   Educational Webcast
NAFLD/NASH   Educational Webcast
Advances in NAFLD/NASH   Educational Webcast
New Advances in NASH Diagnostics and Prognostics   Educational Webcast
New Advances in NASH Diagnostics and Prognostics   Educational Webcast
Pearls and Pitfalls update on emerging therapies in NASH   Educational Webcast
Abstract Library
1.Incretin-based investigational therapies for the treatment of MASLD/MASH
 

Diabetes Res Clin Pract. 2024 Apr 16:111675. doi: 10.1016/j.diabres.2024.111675.Online ahead of print.

 

Bram Brouwers 1, Girish Rao 2, Yuanyuan Tang 2, Ángel Rodríguez 3, Leonard C Glass 2, Mark L Hartman 2
 
2.Impacts of glucagon-like peptide-1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease cirrhosis and type 2 diabetes
 

Aliment Pharmacol Ther. 2024 May;59(9):1096-1110. doi: 10.1111/apt.17925. Epub 2024 Mar 27.

 

Mohamed I Elsaid 1 2 3, Na Li 4, Stephen A Firkins 5, Vinod K Rustgi 6 7, Electra D Paskett 8 9, Chathur Acharya 4, K Rajender Reddy 10, Chien Wei Chiang 1, Khalid Mumtaz 4
 
3.Global prevalence of MAFLD-related hepatocellular carcinoma: A systematic review and meta-analysis
 

Clin Mol Hepatol. 2024 Apr 16. doi: 10.3350/cmh.2024.0109. Online ahead of print.

 

Harry Crane 1, Guy D Eslick 2, Cameron Gofton 1 3, Anjiya Shaikh 4, George Cholankeril 5, Mark Cheah 6, Jian-Hong Zhong 7, Gianluca Svegliati-Baroni 8, Alessandro Vitale 9, Beom Kyung Kim 10, Sang Hoon Ahn 10, Mi Na Kim 10, Simone Strasser 11, Jacob George 1
 
4.Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease
 

Hepatology. 2024 May 1;79(5):1212-1219. doi: 10.1097/HEP.0000000000000670.Epub 2023 Nov 9.

 

Fasiha Kanwal 1 2 3, Brent A Neuschwander-Tetri 4, Rohit Loomba 5, Mary E Rinella 6
 
5.High concordance between nonalcoholic fatty liver disease and metabolic dysfunction associated steatotic liver disease in the TARGET-NASH real world cohort
 

Am J Gastroenterol. 2024 Apr 8. doi: 10.14309/ajg.0000000000002796. Online ahead of print.

 

A Sidney Barritt 4th 1, Feng Yu 2, Andrea R Mospan 2, Philip Newsome 3, Michael Roden 4, Heather L Morris 2, Rohit Loomba 5, Brent A Neuschwander-Tetri 6; TARGET-NASH investigators
 
6.The effects of food insecurity on hepatic steatosis and fibrosis in people with HIV
 

ClinGastroenterolHepatol. 2024Apr5:S15423565(24)002994.doi:10.1016/j.cgh.2024.03.017. Online ahead of print.

 

Ani Kardashian 1, Audrey Lloyd 2, Eduardo Vilar-Gomez 3, Susanna Naggie 4, Mark S Sulkowski 5, Tinsay Woreta 5, Jordan E Lake 6, Holly Crandall 3, Rohit Loomba 7, Laura A Wilson 8, Richard K Sterling 9, Sonya Heath 10, Samer Gawrieh 11, Naga P Chalasani 11, Jennifer C Price 12; HIV NASH Clinical Research Network
 
7.Epidemiology of NAFLD - Focus on diabetes
 

Diabetes Res Clin Pract. 2024 Apr 2:210:111648. doi: 10.1016/j.diabres.2024.111648.Online ahead of print.

 

Zobair M Younossi 1, Linda Henry 2
 
8.Evolution of liver fibrosis in diabetic patients with NAFLD in a follow-up study: Hepatoprotective effects of sodium-glucose co-transporter-2 inhibitors
 

Dig Liver Dis. 2024 Apr;56(4):551-558. doi: 10.1016/j.dld.2023.09.023. Epub 2023 Oct 14.

 

Rosa Lombardi 1, Alessandro Mantovani 2, Annalisa Cespiati 3, Paolo Francione 4, Gabriele Maffi 3, Elena Del Zanna 3, Claudio Maffeis 5, Antonio Colecchia 6, Nicola Passigato 7, Alberto Ferrarese 7, Caterina Daniela Cusumanu 7, Rosanna Villani 8, Emanuela Orsi 9, Valeria Grancini 9, Lorena Airaghi 10, Daniela Bignamini 10, Gaetano Serviddio 8, Giovanni Targher 11, Paola Dongiovanni 10, Silvia Fargion 12, Anna Ludovica Fracanzani 3
 
9.Paediatric steatotic liver disease has unique characteristics: A multisociety statement endorsing the new nomenclature
 

J Pediatr Gastroenterol Nutr. 2024 Mar 26. doi: 10.1002/jpn3.12156. Online ahead of print.

 

European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN); Pietro Vajro; European Association for the Study of the Liver (EASL); North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN); Latin-American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (LASPGHAN); Asian Pan-Pacific Society for Pediatric Gastroenterology, Hepatology and Nutrition (APPSPGHAN); Pan Arab Society for Pediatric Gastroenterology and Nutrition (PASPGHAN); Commonwealth Association of Paediatric Gastroenterology & Nutrition (CAPGAN); Federation of International Societies of Pediatric Hepatology, Gastroenterology and Nutrition (FISPGHAN)

Collaborators

Ulrich Baumann, Bart G P Koot, Emer Fitzpatrick, Jake Mann, Pietro Vajro, Aleksander Krag, Debbie Shawcross, Sven Francque, Tobias Böttler, Benjamin D Gold, Jenifer R Lightdale, Marialena Mouzaki, Norberto Rodriguez-Baez, Rohit Kohli, Vicky L Ng, Daniel D'Agostino, Gilda Porta, José Spolidoro, Miguel Klünder-Klünder, Rodrigo Vázquez-Frias, Anupam Sibal, Jae Sung Ko, Kyung Mo Kim, Suporn Treepongkaruna, Yen-Hsuan Ni, Mohamed El-Guindi, Neelam Mohan, Elvira Verduci, Iqbal Memon, Mahmoud Bozo, Marcela Godoy, Marina Orsi, Marion Aw, Robert Bandsma, Samar Ibrahim, Stavra Xanthakos, Suporn Treepongkaruna, Tania Mitsinikos
 
10.THE GLOBAL EPIDEMIOLOGY OF NON-ALCOHOLIC FATTY LIVER DISEASE AND NON-ALCOHOLIC STEATOHEPATITIS AMONG PATIENTS WITH TYPE 2 DIABETES
 

ClinGastroenterolHepatol. 2024Mar21:S15423565(24)002878.doi:10.1016/j.cgh.2024.03.006. Online ahead of print.

 

Zobair M Younossi 1, Pegah Golabi 2, Jillian Kallman Price 3, Soroor Owrangi 4, Nagashree Gundu-Rao 5, Romona Satchi 5, James Paik 2
 
11.Accuracy, Reliability, and Comprehensibility of ChatGPT-Generated Medical Responses for Patients With Nonalcoholic Fatty Liver Disease
 

Clin Gastroenterol Hepatol. 2024 Apr;22(4):886-889.e5. doi: 10.1016/j.cgh.2023.08.033.Epub 2023 Sep 15.

Nicola Pugliese 1, Vincent Wai-Sun Wong 2, Jörn M Schattenberg 3, Manuel Romero-Gomez 4, Giada Sebastiani 5; NAFLD Expert Chatbot Working Group; Alessio Aghemo 14

Collaborators

NAFLD Expert Chatbot Working Group: 

Laurent Castera 6, Cesare Hassan 7, Pinelopi Manousou 8, Luca Miele 9, Raquel Peck 10, Salvatore Petta 11, Luca Valenti 12, Zobair M Younossi 13
 
12.The first MASH drug therapy on the horizon: Current perspectives of resmetirom
 

Liver Int. 2024 Apr 5. doi: 10.1111/liv.15930. Online ahead of print.

 

Salvatore Petta 1, Giovanni Targher 2 3, Stefano Romeo 4 5 6, Utpal B Pajvani 7, Ming-Hua Zheng 8 9, Alessio Aghemo 10 11, Luca V C Valenti 12 13
 
13.No correlation between MASLD and poor outcome of Atezolizumab-Bevacizumab therapy in patients with advanced HCC
 

Liver Int. 2024 Apr;44(4):931-943. doi: 10.1111/liv.15833. Epub 2024 Jan 30.

 

Francisca-Dora Copil 1, Claudia Campani 2, Marie Lequoy 3, Philippe Sultanik 1, Lorraine Blaise 4, Mathilde Wagner 5, Nathalie Ganne-Carrié 2 4, Violaine Ozenne 3, Dominique Thabut 1 6, Jean-Charles Nault 2 4, Vlad Ratziu 1 6, Manon Allaire 1 2 7
 
14.Cardiac remodelling in non-alcoholic fatty liver disease in the general population
 

Liver Int. 2024 Apr;44(4):1032-1041. doi: 10.1111/liv.15844. Epub 2024 Jan 31.

 

Frederik Kostka 1, Till Ittermann 2, Stefan Groß 3 4, Fabian Christopher Laqua 5, Robin Bülow 1 4, Henry Völzke 2, Marcus Dörr 3 4, Jens Peter Kühn 6, Marcello Ricardo Paulista Markus 3 7, Marie-Luise Kromrey 1
 
15.Inflammatory Bowel Diseases and Non-Alcoholic Fatty Liver Disease: Piecing a Complex Puzzle Together
 

Int J Mol Sci. 2024 Mar 14;25(6):3278. doi: 10.3390/ijms25063278.

 

Rossella Maresca 1, Irene Mignini 1, Simone Varca 1, Valentin Calvez 1, Fabrizio Termite 1, Giorgio Esposto 1, Lucrezia Laterza 1, Franco Scaldaferri 1, Maria Elena Ainora 1, Antonio Gasbarrini 1, Maria Assunta Zocco 1
 
16.Velacur ACE outperforms FibroScan CAP for diagnosis of MASLD
 

Hepatol Commun. 2024 Mar 22;8(4):e0402. doi: 10.1097/HC9.0000000000000402.eCollection 2024 Apr 1.

 

Rohit Loomba 1, Alnoor Ramji 2, Tarek Hassanein 3, Eric M Yoshida 2, Emily Pang 4, Caitlin Schneider 5, Michael P Curry 6, Nezam H Afdhal 6
 
17.Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease
 

JAMA. 2024 Mar 21. doi: 10.1001/jama.2024.1447. Online ahead of print.

 

Huapeng Lin 1 2, Hye Won Lee 3, Terry Cheuk-Fung Yip 1 2, Emmanuel Tsochatzis 4, Salvatore Petta 5, Elisabetta Bugianesi 6, Masato Yoneda 7, Ming-Hua Zheng 8, Hannes Hagström 9 10, Jérôme Boursier 11 12, José Luis Calleja 13, George Boon-Bee Goh 14, Wah-Kheong Chan 15, Rocio Gallego-Durán 16, Arun J Sanyal 17, Victor de Lédinghen 18, Philip N Newsome 19, Jian-Gao Fan 20, Laurent Castéra 21, Michelle Lai 22, Stephen A Harrison 23 24, Céline Fournier-Poizat 25, Grace Lai-Hung Wong 1 2, Grazia Pennisi 5, Angelo Armandi 6, Atsushi Nakajima 7, Wen-Yue Liu 26, Ying Shang 9, Marc de Saint-Loup 11, Elba Llop 13, Kevin Kim-Jun Teh 14, Carmen Lara-Romero 16, Amon Asgharpour 17, Sara Mahgoub 19, Mandy Sau-Wai Chan 25, Clemence M Canivet 11 12, Manuel Romero-Gomez 16, Seung Up Kim 3, Vincent Wai-Sun Wong 1 2; VCTE-Prognosis Study Group
 
18.Approaching the Sarcopenic Patient with Nonalcoholic Steatohepatitis-related Cirrhosis
 

J Clin Transl Hepatol. 2024 Mar 28;12(3):278-286. doi: 10.14218/JCTH.2023.00207.Epub 2024 Jan 26.

 

Paolo Gallo 1, Valentina Flagiello 1, Andrea Falcomatà 1, Giulia Di Pasquale 1, Giorgio D'Avanzo 1, Francesca Terracciani 1, Antonio Picardi 1 2, Umberto Vespasiani-Gentilucci 1 2
 
19.Impact of age on NIS2+™ and other non-invasive blood tests for the evaluation of liver disease and detection of at-risk MASH
 

JHEP Rep. 2024 Jan 19;6(4):101011. doi: 10.1016/j.jhepr.2024.101011. eCollection 2024 Apr.

 

Quentin M Anstee 1 2, Jeremy Magnanensi 3, Yacine Hajji 3, Alexandra Caron 3, Zouher Majd 3, Christian Rosenquist 3, Dean W Hum 3, Bart Staels 4, Margery A Connelly 5, Rohit Loomba 6, Stephen A Harrison 7 8, Vlad Ratziu 9, Arun J Sanyal 10
 
20.Aspirin for Metabolic Dysfunction-Associated Steatotic Liver Disease Without Cirrhosis: A Randomized Clinical Trial
 

JAMA. 2024 Mar 19;331(11):920-929. doi: 10.1001/jama.2024.1215.

 

Tracey G Simon 1 2 3, Robert M Wilechansky 1 2 4, Stefania Stoyanova 4, Alessandra Grossman 4, Laura E Dichtel 2 5, Georg M Lauer 2 4, Karen K Miller 2 5, Yujin Hoshida 6, Kathleen E Corey 1 2 4, Rohit Loomba 7, Raymond T Chung 1 2 4, Andrew T Chan 1 2 4
 
21.Non-Hispanic Black persons with nonalcoholic fatty liver disease have lower rates of advanced fibrosis, cirrhosis, and liver-related events even after controlling for clinical risk factors and PNPLA3 genotype
 

Am J Gastroenterol. 2024 Mar 14. doi: 10.14309/ajg.0000000000002756. Online ahead of print.

 

Niharika Samala 1, Yuchen Xin 2, Laura A Wilson 2, Katherine Yates 2, Rohit Loomba 3, Jay H Hoofnagle 4, Naga Chalasani 1; NASH Clinical Research Network
 
22.The pathophysiology of MASLD: an immunometabolic perspective
 

Expert Rev Clin Immunol. 2024 Apr;20(4):375-386.doi:10.1080/1744666X.2023.2294046. Epub 2023 Dec 27.

 

Julian Schwärzler 1, Felix Grabherr 1, Christoph Grander 1, Timon E Adolph 1, Herbert Tilg 1
 
23.Relationship Between Serum ß-Hydroxybutyrate and Hepatic Fatty Acid Oxidation in Individuals with Obesity and NAFLD
 

Am J Physiol Endocrinol Metab. 2024 Feb 21. doi: 10.1152/ajpendo.00336.2023.Online ahead of print.

 

Mary P Moore 1, Grace Shryack 1, Isabella Alessi 1, Nicole Wieschhaus 2, Grace M Meers 3, Sarah A Johnson 4, Andrew A Wheeler 5, Jamal A Ibdah 6, Elizabeth J Parks 1, R Scott Rector 7
 
24.Development of Cilofexor, an intestinally-biased Farnesoid X Receptor agonist, for the treatment of fatty liver disease
 

J Pharmacol Exp Ther. 2024 Feb 26:JPET-AR-2023001900. doi:10.1124/jpet.123.001900.Online ahead of print.

 

David Hollenback 1, Eva Hambruch 2, Gero Fink 2, Manfred Birkel 2, Andreas Schulz 2, Martin Hornberger 2, Kathy Liu 3, Kelly MacLennan Staiger 4, Helen Desiree Krol 2, Ulrich Deuschle 2, Christoph Steeneck 2, Olaf Kinzel 2, John T Liles 3, Grant Budas 3, William J Watkins 3, Claus Kremoser 5
 
25.Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study
 

ClinGastroenterolHepatol. 2024Mar4:S15423565(24)00226X.doi:10.1016/j.cgh.2024.02.022. Online ahead of print.

 

Stephen A Harrison 1, Juan P Frias 2, K Jean Lucas 3, Gary Reiss 4, Guy Neff 5, Sureka Bollepalli 6, Yan Su 7, Doreen Chan 8, Erik J Tillman 8, Ali Moulton 8, Brittany de Temple 8, Arian Zari 8, Reshma Shringarpure 9, Timothy Rolph 8, Andrew Cheng 8, Kitty Yale 8
 
View More
 

HEPATITIS

HBV
HCV
HDV

CLD HEALTH OUTCOMES

CIRRHOSIS

Cirrhosis
HE
HRS
Thrombocytopenia

NASH

Slide Library
Publications
Webcasts
Abstract Library Committee Members

CHOLESTATIC

PBC

HCC

Slide Library
Publications
Webcasts
Algorithm
Abstract Library Committee Members

ALCOHOL LIVER DISEASE

Recorded Educational Webinar

PEDIATRIC LIVER DISEASE

Webcasts
Slide Library
Abstract Library

About CLDF

Board of Trustees
Board of Advisors/Faculty
CLDF Committees
2024 GI Fellow Board of Advisors

Other Resources

Journal Abstracts

Subscribe

Be the first to know about our latest upcoming programs and events!
CLDF

Follow us
Facebook
Twitter
Youtube
LiverQ
The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2024 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.